Note 2 - Summary of Significant Accounting Policies (Tables)

9 Months Ended

Sep. 30, 2022

Notes Tables

Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]

	September 30,		December 31,
	2022		2021
Cash and cash equivalents	$	3,868	$	7,504
Restricted cash included in other assets		152		475
Total cash, cash equivalents, and restricted cash in the condensed consolidated balance sheets	$	4,020	$	7,979

Schedules of Concentration of Risk, by Product [Table Text Block]

	Three Months Ended September 30,				Nine Months Ended September 30,
	2022		2021		2022		2021
Avenova Spray	$	1,939	$	2,145	$	5,778	$	6,358
DERMAdoctor		1,319		—		3,115		—
NeutroPhase		—		—		657		175
Other products		558		114		1,193		479
Total product revenue, net		3,816		2,259		10,743		7,012
Other revenue, net		10		6		18		19
Total sales, net	$	3,826	$	2,265	$	10,761	$	7,031

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

	September 30,			December 31,
Major distribution partner	2022			2021
Avenova Spray Pharmacy Distributor A		24	%		11	%
Avenova Spray Pharmacy Distributor B		*	%		13	%
Major U.S. Retailer A		20	%		33	%

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

	Three Months Ended September 30, 2022										Nine Months Ended September 30, 2022
	As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised			As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised
Sales
Product revenue, net	$	3,268		$	265	$	283	$	3,816		$	8,934		$	851	$	959	$	10,743
Product cost of goods sold
Product cost of goods sold		1,168			-		283		1,451			3,776			-		959		4,735
Operating expenses
Sales and marketing		1,570			265		-		1,835			5,009			851		-		5,860
Net loss and comprehensive loss		(136	)		-		-		(136	)		(2,402	)		-		-		(2,402	)
Net loss per share (basic and diluted)		(0.10	)		-		-		(0.10	)		(0.15	)		-		-		(0.15	)

	Three Months Ended September 30, 2021										Nine Months Ended September 30, 2021
	As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised			As Previously Reported			Selling Commissions		Fulfillment Fees		As Revised
Sales
Product revenue, net	$	1,834		$	206	$	219	$	2,259		$	5,761		$	619	$	632	$	7,012
Product cost of goods sold
Product cost of goods sold		493					219		712			1,562					632		2,194
Operating expenses
Sales and marketing		1,855			206				2,061			5,323			619				5,942
Net loss and comprehensive loss		(2,289	)		-		-		(2,289	)		(5,666	)		-		-		(5,666	)
Net loss per share (basic and diluted)		(0.05	)		-		-		(0.05	)		(0.13	)		-		-		(0.13	)

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Three Months Ended September 30,						Nine Months Ended September 30,
Numerator	2022			2021			2022			2021
Net loss	$	(136	)	$	(2,289	)	$	(2,402	)	$	(5,666	)
Less: Increase in accumulated deficit due to Series B Preferred Stock conversion price		5,657			—			5,657			—
Net loss attributable to common stockholders, basic and diluted	$	(5,793	)	$	(2,289	)	$	(8,059	)	$	(5,666	)
Denominator
Weighted average shares outstanding, basic and diluted		56,133			44,921			53,007			43,100
Net loss per share, basic and diluted	$	(0.10	)	$	(0.05	)	$	(0.15	)	$	(0.13	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

	As of September 30,
	2022		2021
Series B Preferred Stock common stock equivalents		64,561		—
Stock options		4,743		3,947
Stock warrants		2,282		7,082
		71,586		11,029